| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10967323 | Vaccine | 2012 | 9 Pages |
Abstract
⺠We investigated the cost-effectiveness of replacing PCV-7 with PCV-13. ⺠We used the outcome of a dynamic infectious disease model. ⺠We used vaccine-type specific disease outcomes obtained from a hospital dataset. ⺠The cost-effectiveness of PCV-13 is borderline cost effective. ⺠The outcome depends on a number of assumptions for which evidence is limited.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Albert Jan van Hoek, Yoon Hong Choi, Caroline Trotter, Elizabeth Miller, Mark Jit,